Amsha Africa Foundation (AAF) is now a member of the Netzkraft Movement which is an international body for peace, human rights and environment within the United Nations.

Check out this informational video about Aquaponics, the practice of combining fish farming and hyrodoponics.
http://www.youtube.com/watch?v=26xpMCXP9bw&feature=youtu.be

Amsha Africa Foundation has been working with various partners throughout Africa and in the U.S. to raise awareness on Aquaponics and it's potential in the third world countries.

Video is courtesy of Purdue Extension University, Sea Grant, and NOAA

Neonicotinoid, known as “neonics” for short, is a farm pesticide produced primarily by the German chemical giant Bayer, widely used in the U.S. to coat a massive 142 million acres of corn, wheat, soy and cotton seeds. They are also common ingredients in many home gardening products.

Today, Amsha Africa Foundation submitted its annual Form 990-N to the U.S. Department of the Treasury Internal Revenue Service.

Most small tax-exempt organizations whose annual gross receipts are normally $50,000 or less in the U.S. are required to electronically submit Form 990-N, also known as the e-Postcard, unless they choose to file a complete Form 990 or Form 990-EZ instead.

Amsha Africa Foundation has been in compliance with the IRS filing regulation since its formation and our filings and other non profit status documents can be found in the link below.

http://amshaafrica.org/about-us/our-non-profit-status.html

More Details on the Form 990:

http://www.irs.gov/Charities-&-Non-Profits/Annual-Electronic-Filing-Requirement-for-Small-Exempt-Organizations--Form-990-N-(e-Postcard)

Wishing you and your families “The Merriest Christmas and Happy New Year!!!

Thank you for all your support in 2012.

Take care and be safe over the holidays.

AAF Team!

The world's first potential malaria vaccine proved only 30 percent effective in African babies in a crucial trial, calling into question whether it can be a useful weapon in the fight against the deadly disease.

The surprisingly poor result for the vaccine, which GlaxoSmithKline has been developing for three decades, and propagated to African communities by organizations such as AAF, leaves several years of work ahead before a protective malaria shot could be ready for countries that desperately need one.